Abstract:Hypertrophic cardiomyopathy (HCM) is the most common genetically inherited cardiomyopathy with an autosomal dominant inheritance pattern. A disease-causing gene is found between 34% and >60% of the times and the two most frequently mutated genes, which encode sarcomeric proteins, are MYBPC3 and MYH7. HCM is a diagnosis of exclusion since secondary causes of left ventricular hypertrophy should first be ruled out. These include hypertension, aortic stenosis, infiltrative disease, metabolic and endocrine disorders, mitochondrial cardiomyopathies, neuromuscular disorders, malformation syndromes and some chronic drug use. The disease is characterized by great heterogeneity of its clinical manifestations, however diastolic dysfunction and increased ventricular arrhythmogenesis are commonly seen. Current HCM therapies focus on symptom management and prevention of sudden cardiac death. Symptom management includes the use of pharmacological agents, elimination of medication promoting outflow track obstruction, control of comorbid conditions and invasive procedures, whereas in the prevention of sudden cardiac death, implantable cardiac defibrillators and antiarrhythmic drugs are used. A targeted therapy for LVOTO represented by allosteric cardiac myosin inhibitors has been developed. In terms of sport participation, a more liberal approach is recently recommended, after careful evaluation and common-shared decision. The application of the current therapies has lowered HCM mortality rates to <1.0%/year, however it appears to have shifted focus to heart failure and atrial fibrillation, as the predominant causes of disease-related morbidity and mortality and, therefore, unmet treatment need. With improved understanding of the genetic and molecular basis of HCM, the present decade will witness novel treatments for disease prevention and modification.

Hypertrophic Cardiomyopathy: From Medical Treatment to Advanced Heart Failure Therapies

A systematic review of present and future pharmaco‐structural therapies for hypertrophic cardiomyopathy

Advancements in the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Comprehensive Review

Medical Treatment Strategies for Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline

Obstructive hypertrophic cardiomyopathy: a review of new therapies

Novel Pharmacotherapy in Hypertrophic Cardiomyopathy

Medical Therapies to Improve Left Ventricular Outflow Obstruction and Diastolic Function in Hypertrophic Cardiomyopathy

Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond

Review of Contemporary Invasive Treatment Approaches and Critical Appraisal of Guidelines on Hypertrophic Obstructive Cardiomyopathy: State-of-the-Art Review

Considerations for drug trials in hypertrophic cardiomyopathy

Novel Cardiac Myosin Inhibitor Therapy for Hypertrophic Cardiomyopathy in Adults: A Contemporary Review

Medical Therapies with Potential to Become Part of the Therapeutic Armamentarium

The Revolution of Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy

Non-pharmaceutical Interventions for Hypertrophic Cardiomyopathy: A Mini Review

An overview of the treatments for hypertrophic cardiomyopathy

Gene therapy in cardiology: is a cure for hypertrophic cardiomyopathy on the horizon?

Advanced Heart Failure: Therapeutic Options and Challenges in the Evolving Field of Left Ventricular Assist Devices

Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside

Long‐term post‐transplantation outcomes in patients with hypertrophic cardiomyopathy: Single‐center 35‐year experience

Current and emerging perspectives on pathophysiology, diagnosis, and management of hypertrophic cardiomyopathy